Hopes are alive that the spread of coronavirus may soon be curtailed as some scientists in Isreal have announced a significant breakthrough in the development of COVID-19 vaccine in their four-year-old research.
According to a statement published by the Migal Galilee Research Institute (MIGAL) on its website on Thursday, February 27, some of its researchers said they had developed an effective vaccine against avian coronavirus infectious bronchitis virus (IBV).
The researchers said they will soon create a human vaccine against coronavirus (COVID-19), the viral disease that is spreading across the world like a raging wildfire with death tolls increasing at an exponential rate.
Judicial Sketch learns that IBV is a disease affecting animals and the vaccine they developed against it has been proven in pre-clinical trials.
The research which spanned four years was funded by Israel’s Ministry of Science and Technology in cooperation with Israel’s Ministry of Agriculture, MIGAL.
According to the researchers, the vaccine against the animal disease which they have just created will lead to the rapid creation of a vaccine against coronavirus which is affecting humans.
They said they have now made required genetic adjustments to adapt the vaccine to COVID-19, that is, the coronavirus affecting humans. They are currently working to achieve the safety approvals that will enable in-vivo testing, enable the initiation of production of a vaccine to counter the coronavirus epidemic.
They also discovered that the poultry coronavirus has high genetic similarity to the human COVID-19, and that it uses the same infection mechanism. This, according to the researchers, increases the likelihood of achieving an effective human vaccine in a very short period of time.
David Zigdon who is MIGAL’s chief executive officer said: “Given the urgent global need for a human coronavirus vaccine, we are doing everything we can to accelerate development. Our goal is to produce the vaccine during the next 8-10 weeks, and to achieve safety approval in 90 days.”
He said the vaccine will be in an oral form which will make it more accessible to the public.
Chen Katz, MIGAL’s biotechnology group leader, also said “the scientific framework for the vaccine is based on a new protein expression vector, which forms and secretes a chimeric soluble protein that delivers the viral antigen into mucosal tissues by self-activated endocytosis (a cellular process in which substances are brought into a cell by surrounding the material with cell membrane, forming a vesicle containing the ingested material), causing the body to form antibodies against the virus.